Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors.

ABSTRACT:

Background

There have been concerns about the use of tumor necrosis factor inhibitors (TNFi) for autoimmune disease in patients with recently diagnosed cancer. We assessed the survival of patients with rheumatoid arthritis (RA) and newly diagnosed early breast cancer (BC) treated with TNFi in the first two years after BC diagnosis.

Methods

We identified patients in two datasets: (1) Optum's de-identified Clinformatics^® Data Mart Database (CDM), (2) Surveillance, Epidemiology, and End Results program (SEER) and Texas Cancer Registry (TCR) Medicare-linked cohort. We grouped patients according to whether they received TNFi, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) only, or no DMARDs within 2 years after BC. Outcomes were overall surviva

SUBMITTER: Ruiz JI 

PROVIDER: S-EPMC11808625 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature